Validation of New Biomarkers for Predicting No-Reflow in STEMI Patients Undergoing Primary PCI

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2025
To evaluate the diagnostic value of the selected emerging biomarkers in predicting the no-reflow phenomenon among patients presenting with STEMI undergoing primary PCI. These biomarkers include: HbA1c/C-peptide ratio Albumin-bilirubin (ALBI) score. Neutrophil/HDL ratio
Epistemonikos ID: aaf9d2089772b36f531b2feeaf8cebfbc2f16939
First added on: Aug 21, 2025